Applied BioCode（6598）株式概要アプライド・バイオコード・コーポレーションは、カリフォルニア州でマルチプレックス診断検査製品の設計、開発、商業化を行う。 詳細6598 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析過去5年間で収益は年間11.6%減少しました。 意味のある時価総額がありません ( NT$3B )すべてのリスクチェックを見る6598 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW488,088 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG488,088 investors already sharing narrativesYour Fair ValueNT$Current PriceNT$27.6541.6% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-282m798m2016201920222025202620282031Revenue NT$798.4mEarnings NT$104.5mAdvancedSet Fair ValueView all narrativesApplied BioCode Corporation 競合他社Medimaging Integrated SolutionSymbol: TWSE:6796Market cap: NT$2.3bA Plus BiotechnologySymbol: TWSE:6918Market cap: NT$2.4bWellellSymbol: TWSE:4106Market cap: NT$2.5bCrystalvue MedicalSymbol: TPEX:6527Market cap: NT$1.8b価格と性能株価の高値、安値、推移の概要Applied BioCode過去の株価現在の株価NT$27.6552週高値NT$27.7052週安値NT$19.15ベータ0.711ヶ月の変化14.49%3ヶ月変化21.27%1年変化35.87%3年間の変化5.53%5年間の変化-37.93%IPOからの変化-60.22%最新ニュースReported Earnings • May 16First quarter 2026 earnings released: EPS: NT$0.20 (vs NT$0.35 loss in 1Q 2025)First quarter 2026 results: EPS: NT$0.20 (up from NT$0.35 loss in 1Q 2025). Revenue: NT$217.1m (up 81% from 1Q 2025). Net income: NT$21.0m (up NT$56.7m from 1Q 2025). Profit margin: 9.7% (up from net loss in 1Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.お知らせ • May 05Applied BioCode Announces FDA Clearance for KingFisher™ Nucleic Acid Extraction with BioCode® Respiratory Pathogen Panel for IVD UseApplied BioCode, a leader in multiplex molecular diagnostic solutions, announced a significant enhancement to its BioCode Respiratory Pathogen Panel (RPP) workflow with the addition of nucleic acid extraction claims for the widely used Thermo Fisher Scientific KingFisher Flex platform. This expansion provides clinical laboratories running BioCode RPP with greater workflow flexibility and optimized sample processing capabilities. This enhancement to the BioCode RPP enables seamless integration of the KingFisher Flex extraction platform and the BioCode MDx-3000 automated detection system, expanding the panel’s utility and increasing throughput for respiratory testing. Clinical laboratories using these extraction systems can now streamline their workflows by pairing them with the BioCode RPP, providing an affordable and comprehensive solution for detecting 17 prevalent respiratory pathogens. By improving workflow efficiency, this new claim is expected to enhance patient care by accelerating the delivery of accurate and timely diagnostic results. This submission builds on Applied BioCode’s previous FDA clearance of the BioCode Gastrointestinal Pathogen Panel (GPP) with the KingFisher Flex system, highlighting the company’s ongoing success in validating flexible, high-throughput extraction solutions across its multiplexed panel portfolio. Applied BioCode continues to advance molecular diagnostic solutions that meet the evolving needs of clinical laboratories, supporting patient care with accurate, reliable, and actionable results.Reported Earnings • Mar 13Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: NT$1.96 loss per share (improved from NT$2.88 loss in FY 2024). Revenue: NT$475.2m (up 39% from FY 2024). Net loss: NT$201.2m (loss narrowed 23% from FY 2024). Revenue missed analyst estimates by 5.0%. Earnings per share (EPS) also missed analyst estimates by 17%. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has fallen by 4% per year.お知らせ • Mar 12Applied BioCode Corporation, Annual General Meeting, Jun 11, 2026Applied BioCode Corporation, Annual General Meeting, Jun 11, 2026, at 10:00 Taipei Standard Time. Location: 7 floor no,185, hsin hu 1st rd., neihu district, taipei city TaiwanBoard Change • Dec 30Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Jim Wu was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 12Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2025 results: NT$0.33 loss per share (improved from NT$0.80 loss in 3Q 2024). Revenue: NT$122.8m (up 64% from 3Q 2024). Net loss: NT$33.7m (loss narrowed 56% from 3Q 2024). Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 23%. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 8% per year.最新情報をもっと見るRecent updatesReported Earnings • May 16First quarter 2026 earnings released: EPS: NT$0.20 (vs NT$0.35 loss in 1Q 2025)First quarter 2026 results: EPS: NT$0.20 (up from NT$0.35 loss in 1Q 2025). Revenue: NT$217.1m (up 81% from 1Q 2025). Net income: NT$21.0m (up NT$56.7m from 1Q 2025). Profit margin: 9.7% (up from net loss in 1Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.お知らせ • May 05Applied BioCode Announces FDA Clearance for KingFisher™ Nucleic Acid Extraction with BioCode® Respiratory Pathogen Panel for IVD UseApplied BioCode, a leader in multiplex molecular diagnostic solutions, announced a significant enhancement to its BioCode Respiratory Pathogen Panel (RPP) workflow with the addition of nucleic acid extraction claims for the widely used Thermo Fisher Scientific KingFisher Flex platform. This expansion provides clinical laboratories running BioCode RPP with greater workflow flexibility and optimized sample processing capabilities. This enhancement to the BioCode RPP enables seamless integration of the KingFisher Flex extraction platform and the BioCode MDx-3000 automated detection system, expanding the panel’s utility and increasing throughput for respiratory testing. Clinical laboratories using these extraction systems can now streamline their workflows by pairing them with the BioCode RPP, providing an affordable and comprehensive solution for detecting 17 prevalent respiratory pathogens. By improving workflow efficiency, this new claim is expected to enhance patient care by accelerating the delivery of accurate and timely diagnostic results. This submission builds on Applied BioCode’s previous FDA clearance of the BioCode Gastrointestinal Pathogen Panel (GPP) with the KingFisher Flex system, highlighting the company’s ongoing success in validating flexible, high-throughput extraction solutions across its multiplexed panel portfolio. Applied BioCode continues to advance molecular diagnostic solutions that meet the evolving needs of clinical laboratories, supporting patient care with accurate, reliable, and actionable results.Reported Earnings • Mar 13Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: NT$1.96 loss per share (improved from NT$2.88 loss in FY 2024). Revenue: NT$475.2m (up 39% from FY 2024). Net loss: NT$201.2m (loss narrowed 23% from FY 2024). Revenue missed analyst estimates by 5.0%. Earnings per share (EPS) also missed analyst estimates by 17%. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has fallen by 4% per year.お知らせ • Mar 12Applied BioCode Corporation, Annual General Meeting, Jun 11, 2026Applied BioCode Corporation, Annual General Meeting, Jun 11, 2026, at 10:00 Taipei Standard Time. Location: 7 floor no,185, hsin hu 1st rd., neihu district, taipei city TaiwanBoard Change • Dec 30Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Jim Wu was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 12Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2025 results: NT$0.33 loss per share (improved from NT$0.80 loss in 3Q 2024). Revenue: NT$122.8m (up 64% from 3Q 2024). Net loss: NT$33.7m (loss narrowed 56% from 3Q 2024). Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 23%. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 8% per year.Reported Earnings • Aug 27Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: NT$0.66 loss per share (further deteriorated from NT$0.61 loss in 2Q 2024). Revenue: NT$115.9m (up 14% from 2Q 2024). Net loss: NT$67.5m (loss widened 35% from 2Q 2024). Revenue missed analyst estimates by 7.3%. Earnings per share (EPS) also missed analyst estimates by 53%. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.お知らせ • Jun 07Applied BioCode Corporation Approves Board ElectionsApplied BioCode Corporation at its 2025 Shareholders' General Meeting held on June 6, 2025, approved the election of George J. Lee, Director, Foresee Pharmaceuticals Co. Ltd. and Benjamin Jen, Managing Partner, GRC SinoGreen Fund as Directors. Title and name of the previous position holder: Representative of institutional directors: Independent Director: Ben Liu, Lawyer, InfoShare Tech Law Office and Independent Director: Jack Hsiao, COO, Hsiao Chung-Cheng Healthcare group. Title and name of the new position holder: Representative of institutional directors: Independent Director: James Hsu, Director, TaChuan Investment Ltd. and Independent Director: Jim Wu, Director and Chief Corporate Affairs Officer, TNL Mediagene. Effective date of the new appointment is June 6, 2025.Reported Earnings • May 15First quarter 2025 earnings released: NT$0.35 loss per share (vs NT$0.77 loss in 1Q 2024)First quarter 2025 results: NT$0.35 loss per share (improved from NT$0.77 loss in 1Q 2024). Revenue: NT$120.0m (up 47% from 1Q 2024). Net loss: NT$35.7m (loss narrowed 43% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.お知らせ • May 01Applied BioCode Corporation to Report Q1, 2025 Results on May 08, 2025Applied BioCode Corporation announced that they will report Q1, 2025 results on May 08, 2025Reported Earnings • Mar 20Full year 2024 earnings released: NT$2.88 loss per share (vs NT$2.01 loss in FY 2023)Full year 2024 results: NT$2.88 loss per share (further deteriorated from NT$2.01 loss in FY 2023). Revenue: NT$343.1m (down 13% from FY 2023). Net loss: NT$260.8m (loss widened 59% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings.お知らせ • Mar 14Applied BioCode Corporation, Annual General Meeting, Jun 06, 2025Applied BioCode Corporation, Annual General Meeting, Jun 06, 2025.お知らせ • Mar 06Applied BioCode Corporation to Report Q4, 2024 Results on Mar 13, 2025Applied BioCode Corporation announced that they will report Q4, 2024 results at 9:00 AM, Taipei Standard Time on Mar 13, 2025お知らせ • Jan 14Applied Biocode Announces New Nucleic Acid Extraction Claim for Kingfisher Flex Nucleic Acid Purification System with Biocode Gastrointestinal Pathogen Panel (GPP)Applied BioCode announced a significant enhancement to its BioCode Gastrointestinal Pathogen Panel (GPP) with the addition of nucleic acid extraction claim for the widely adopted ThermoFisher Scientific KingFisher Flex platform. This expansion enables greater workflow flexibility and optimized sample processing capabilities for clinical laboratories running the BioCode GPP. This enhancement to the BioCode GPP allows for seamless integration with KingFisher Flex extraction platform, broadening the panel’s utility and increasing throughput for gastrointestinal testing. Clinical laboratories using these extraction systems can now streamline their operations by pairing them with the BioCode GPP, providing a comprehensive solution to detect 17 of the most prevalent gastrointestinal pathogens. By improving workflow efficiency, the new claim is expected to significantly impact patient care by accelerating the turnaround of accurate and timely diagnostic information. The BioCode GPP now supports multiple extraction platforms, making it one of the most versatile panels in its class for detecting gastrointestinal pathogens in stool samples. This addition aligns with Applied BioCode’s mission to innovate and adapt to the growing demands of healthcare providers, enabling laboratories to maximize the value of their existing instruments while advancing diagnostic capabilities. With its unique Barcoded Magnetic Bead (BMB) technology, the BioCode GPP simplifies and accelerates high-throughput molecular diagnostics, offering an economical, accurate, and comprehensive solution for clinical labs across the U.S. and beyond. This nucleic acid extraction expansion will help laboratories improve their workflows, increase operational flexibility, and expand their diagnostic capabilities.New Risk • Nov 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (NT$2.29b market cap, or US$70.4m).Reported Earnings • Nov 18Third quarter 2024 earnings: EPS and revenues miss analyst expectationsThird quarter 2024 results: NT$0.80 loss per share (further deteriorated from NT$0.54 loss in 3Q 2023). Revenue: NT$74.9m (down 29% from 3Q 2023). Net loss: NT$76.8m (loss widened 76% from 3Q 2023). Revenue missed analyst estimates by 33%. Earnings per share (EPS) also missed analyst estimates by 82%. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 10% per year.お知らせ • Nov 02Applied BioCode Corporation to Report Q3, 2024 Results on Nov 11, 2024Applied BioCode Corporation announced that they will report Q3, 2024 results on Nov 11, 2024Reported Earnings • Aug 29Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2024 results: NT$0.61 loss per share (improved from NT$0.75 loss in 2Q 2023). Revenue: NT$101.6m (up 30% from 2Q 2023). Net loss: NT$50.0m (loss narrowed 18% from 2Q 2023). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) missed analyst estimates by 11%. Over the last 3 years on average, earnings per share has fallen by 13% per year whereas the company’s share price has fallen by 14% per year.お知らせ • Aug 15Applied BioCode Corporation to Report Q2, 2024 Results on Aug 22, 2024Applied BioCode Corporation announced that they will report Q2, 2024 results on Aug 22, 2024お知らせ • Jul 20Applied BioCode Corporation announced that it has received fundingApplied BioCode Corporation announced a private placement to issue common shares on July 19, 2024. The transaction has been approved by shareholders of company.New Risk • Jun 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (NT$2.75b market cap, or US$84.8m).分析記事 • Jun 19Applied BioCode Corporation's (TWSE:6598) Shares Climb 33% But Its Business Is Yet to Catch UpThe Applied BioCode Corporation ( TWSE:6598 ) share price has done very well over the last month, posting an excellent...Reported Earnings • May 19First quarter 2024 earnings: EPS and revenues miss analyst expectationsFirst quarter 2024 results: NT$0.77 loss per share (further deteriorated from NT$0.62 loss in 1Q 2023). Revenue: NT$81.5m (down 1.5% from 1Q 2023). Net loss: NT$63.1m (loss widened 24% from 1Q 2023). Revenue missed analyst estimates by 9.4%. Earnings per share (EPS) also missed analyst estimates by 71%. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings.お知らせ • Apr 15Applied BioCode Announces the Launch of the STI + Resistance Panel Assay for Research Use OnlyApplied BioCode Inc. announced the launch of its latest innovation, the BioCode STI + Resistance Panel (RUO). This multiplex nucleic acid amplification test is meticulously crafted to qualitatively detect DNA from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), Mycoplasma genitalium (MG), as well as macrolide-resistant and fluoroquinolone-resistant single nucleotide polymorphism (SNP) mutations in a single reaction. The panel is exclusively intended for research purposes and is not intended for diagnostic procedures. Engineered with precision for seamless integration with the BioCode MDx-3000 automated system, it delivers timely test results approximately 4 hours post-DNA extraction. The system boasts an intuitive protocol and reporting software, meticulously tailored to enhance workflows in research clinical microbiology lab environments, accommodating up to 96 samples per test run.お知らせ • Mar 22Applied BioCode Announces CEO ChangesApplied BioCode announced the retirement of Chris Bernard as Chief Executive Officer. Chris Bernard has served as CEO for the past two years and has been instrumental in guiding the company through a period of growth and innovation. During his tenure, Chris played a pivotal role in advancing Applied BioCode’s strategic initiatives and driving the company’s commitment to delivering cutting-edge solutions to the molecular diagnostics market. His leadership and dedication have been invaluable in positioning Applied BioCode as a leader in multiplex testing technologies. Following his retirement, Winston Ho, Ph.D., Founder and President, will step into the role of Chief Executive Officer until a new CEO is appointed.Reported Earnings • Mar 17Full year 2023 earnings released: NT$2.01 loss per share (vs NT$2.26 loss in FY 2022)Full year 2023 results: NT$2.01 loss per share (improved from NT$2.26 loss in FY 2022). Revenue: NT$395.2m (up 1.2% from FY 2022). Net loss: NT$164.2m (loss narrowed 11% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 23% per year and the company’s share price has also fallen by 23% per year.お知らせ • Mar 08Applied BioCode Corporation, Annual General Meeting, May 27, 2024Applied BioCode Corporation, Annual General Meeting, May 27, 2024. Location: Lily Conference, (2F, No. 327, Sec. 1, Tiding Blvd., Neihu Dist Taipei City Taiwan Agenda: To consider 2023 operation report; to consider audit committee review report on the 2023 financial statements; to consider amendment to the rules of procedures for the board of directors meeting; to consider 2023 business report and 2023 consolidated financial report; to consider 2023 deficit compensation; to consider adoption of the amended and restated memorandum and articles of association; to consider amendment to procedures for acquisition or disposal of assets; and to consider other issues.New Risk • Dec 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.9% average weekly change). Market cap is less than US$100m (NT$2.13b market cap, or US$67.8m).Reported Earnings • Nov 15Third quarter 2023 earnings released: NT$0.53 loss per share (vs NT$0.54 loss in 3Q 2022)Third quarter 2023 results: NT$0.53 loss per share (improved from NT$0.54 loss in 3Q 2022). Revenue: NT$105.8m (down 1.9% from 3Q 2022). Net loss: NT$43.7m (flat on 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.お知らせ • Sep 29Applied BioCode Appoints Beth Laderman as Chief Scientific OfficerApplied BioCode announced that Beth Laderman has been appointed as their new Chief Scientific Officer signaling a significant step in the company’s expansion. With 25 years of experience in the medical diagnostic field, Dr. Laderman brings expertise from her previous roles at HYCOR Biomedical and Biomerica Inc. Her appointment is set to drive Applied BioCode’s focus on expanding its MDx-3000 platform and exploring new applications for its patented barcoded magnetic beads (BMBs). Dr. Laderman joins as Applied BioCode continues to expand its US commercial footprint and explores US & global expansion and new opportunities for their technology. With its current portfolio of PCR-based, multiplex molecular diagnostic assays in the respiratory and gastrointestinal markets, along with the new BioCode Fungal Panel RUO approval, the company remains steadfast in its mission in having R&D fully support the commercial enterprise by delivering transformative solutions for high-throughput diagnostics. Dr. Laderman’s appointment as CSO of Applied BioCode marks an exciting chapter in the company’s journey to revolutionize diagnostics and life sciences. Her deep knowledge, leadership skills, and dedication to innovation are expected to drive the company’s research and development initiatives to new heights.お知らせ • Sep 25Applied BioCode Corporation Announces the Resignation of Michael Sean Aye as Research and Development OfficerApplied BioCode Corporation announced the resignation of Michael Sean Aye as research and development officer, effective September 23, 2023. Reason for the change: Personal career planning.Reported Earnings • Aug 30Second quarter 2023 earnings released: NT$0.75 loss per share (vs NT$0.39 loss in 2Q 2022)Second quarter 2023 results: NT$0.75 loss per share (further deteriorated from NT$0.39 loss in 2Q 2022). Revenue: NT$78.5m (down 27% from 2Q 2022). Net loss: NT$61.2m (loss widened 94% from 2Q 2022). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings.お知らせ • Jun 15Applied BioCode Corporation Announces the Change of Representative of Institutional DirectorApplied BioCode Corporation announced Name of the previous position holder:Wen-Chin Hung. Resume of the previous position holder:Wen-Chin Hung/Mingwei Corporation. 5.Name of the new position holder:Lizzie lee. Resume of the new position holder:Lizzie Lee/GRC SinoGreen Capital Co. Ltd. Risk Management Director. Reason for the change: Institutional director assigned a representative.お知らせ • Jun 13Applied Biocode Corporation Announces the Launch of the Fungal Panel Assay for Research UseApplied BioCode Corporation announced that it now offers Fungal Panel on the BioCode® MDx-3000 system for research use only (RUO). The Fungal Panel Assay was developed to detect the most common agents of invasive fungal infections (IFIs) particularly in lower respiratory samples. This Panel detects fungal agents includingAspergillus species, Rhizopus, Mucor, Rhizomucor, Cunninghamella, Lomentospora, Fusarium, Cryptococcus, Pneumocystis jirovecii and dimorphic pathogens (Coccidioides immitis/posadasii, Histoplasma capsulatum and Blastomyces dermatiditis). The panel will provide 20 distinct results along with an internal control and will be primarily for use on the company's BioCode MDx-3000 instrument. Detection of IFI is difficult, and recovery by culture could take several days to weeks with poor sensitivity. Faster and more sensitive detection of IFI can be helpful in clinical management, especially for immunocompromised patients.Reported Earnings • Mar 26Full year 2022 earnings: Revenues and EPS in line with analyst expectationsFull year 2022 results: NT$2.26 loss per share (further deteriorated from NT$2.02 loss in FY 2021). Revenue: NT$390.3m (up 22% from FY 2021). Net loss: NT$184.7m (loss widened 12% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.お知らせ • Jan 05Applied BioCode Corporation Announces Resignation of Craig Griz Adams as Sales DirectorApplied BioCode Corporation announced resignation of Craig Griz Adams as Sales Director due to personal career planning, effective January 4, 2023.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Director Benjamin Jen was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Director Benjamin Jen was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Oct 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Director Benjamin Jen was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Aug 26+ 1 more updateApplied BioCode Corporation Announces the Change of Vice President of OperationApplied BioCode Corporation announced the Change of Vice President of Operation. Date of occurrence of the change is August 25, 2022. Name, title, and resume of the previous position holder: N/A. Name, title, and resume of the new position holder: Gerald Kowalski/The Company's Director of Product Development. Type of the change: position adjustment. Reason for the change: Gerald Kowalski was the Director of Product Development and then is promoted to VP of Operation due to the internal position adjustment. Effective date is August 25, 2022.お知らせ • May 18Applied BioCode Corporation Announces Change of Sales DirectorApplied BioCode Corporation announced change of Sales Director. Name, title, and resume of the previous position holder: Michael Jason Scott/Sales Director. Type of the change: Resignation. Effective date is May 17, 2022.Reported Earnings • May 14First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: NT$0.90 loss per share (down from NT$0.29 loss in 1Q 2021). Revenue: NT$54.1m (down 36% from 1Q 2021). Net loss: NT$73.8m (loss widened 209% from 1Q 2021). Revenue exceeded analyst estimates by 10.0%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Price Target Changed • Apr 27Price target decreased to NT$34.00Down from NT$102, the current price target is provided by 1 analyst. New target price is 27% below last closing price of NT$46.75. Stock is down 8.5% over the past year. The company is forecast to post a net loss per share of NT$2.24 next year compared to a net loss per share of NT$2.02 last year.Reported Earnings • Mar 31Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: NT$2.02 loss per share (down from NT$1.33 loss in FY 2020). Revenue: NT$320.0m (up 7.0% from FY 2020). Net loss: NT$165.2m (loss widened 60% from FY 2020). Revenue exceeded analyst estimates by 10.0%. Earnings per share (EPS) missed analyst estimates by 15%. Over the next year, revenue is forecast to stay flat compared to a 31% growth forecast for the industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.お知らせ • Dec 17Applied BioCode Obtains Emergency Use Authorization for CoV-2 Flu Plus AssayApplied BioCode announced that it has received Emergency Use Authorization (EUA) from the US FDA for its BioCode® CoV-2 Flu Plus Assay. This PCR-based, multiplex molecular diagnostic assay can simultaneously detect and differentiate between SARS-CoV-2, Influenza A with subtypes (seasonal H1, 2009 H1N1, H3, Influenza B), and Respiratory Syncytial Virus (RSV) in nasopharyngeal swab specimens. The test is designed to assist physicians in evaluating patients with clinical signs and symptoms respiratory infection. The BioCode® CoV-2 Flu Plus Assay is Applied BioCode’s third EUA authorization from the US FDA for COVID-19 testing. Applied BioCode previously received FDA EUA authorization for the BioCode® SARS CoV-2 Assay and for pooling of up to 5 samples for that assay. The BioCode® CoV-2 Flu Plus Assay is run on the automated high-throughput BioCode® MDx-3000 Molecular System and provides scalable throughput, allowing clinical labs to run up to 564 sample results per day. BioCode® CoV-2 Flu Plus Assay builds on the existing portfolio of high-throughput syndromic assays from Applied BioCode including the FDA 510(k) cleared BioCode Respiratory Pathogen Panel (17 targets), FDA 510(k) cleared BioCode® Gastrointestinal Pathogen Panel (17 targets), and its stand-alone EUA authorized BioCode® SARS-CoV-2 Assay.お知らせ • Nov 24Applied BioCode Launches 28 New Fungal Analyte Specific Reagents in the USApplied BioCode announced that it has released28 Fungal Analyte Specific Reagents (ASRs) for use in molecular tests. (15 ASRs for mold pathogens, 10 ASRs for yeast pathogens, and 3 ASRs to detect dimorphic fungi). These ASR products utilize the company’s proprietary Barcoded Magnetic Bead (BMB) technology for specific detection of targeted organisms. For use as building blocks to develop and validate tests for the diagnosis of infectious diseases, ASRs may be sold to in vitro diagnostic manufacturers, and clinical laboratories regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), as qualified to perform high complexity testing. ASRs may also be sold to organizations that use the reagents to make tests for purposes other than providing diagnostic information to patients and practitioners, e.g., forensic, academic, research, and other nonclinical laboratories. The primer pairs or probes coupled to BMBs are classified as ASRs, which can be used by high-complexity laboratories to develop their own laboratory developed tests (LDTs).Reported Earnings • Nov 12Third quarter 2021 earnings released: NT$0.75 loss per share (vs NT$0.28 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: NT$58.8m (down 40% from 3Q 2020). Net loss: NT$61.1m (loss widened 165% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.分析記事 • Mar 31We're Interested To See How Applied BioCode (TPE:6598) Uses Its Cash Hoard To GrowThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Reported Earnings • Mar 30Full year 2020 earnings released: NT$1.33 loss per share (vs NT$4.36 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: NT$299.0m (up 186% from FY 2019). Net loss: NT$103.5m (loss narrowed 63% from FY 2019). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.お知らせ • Mar 18Applied BioCode Corporation, Annual General Meeting, Jun 07, 2021Applied BioCode Corporation, Annual General Meeting, Jun 07, 2021.分析記事 • Feb 03Introducing Applied BioCode (TPE:6598), A Stock That Climbed 11% In The Last Three YearsThe last three months have been tough on Applied BioCode Corporation ( TPE:6598 ) shareholders, who have seen the share...Is New 90 Day High Low • Feb 02New 90-day low: NT$49.05The company is down 38% from its price of NT$79.60 on 04 November 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 10.0% over the same period.Is New 90 Day High Low • Jan 07New 90-day low: NT$55.00The company is down 48% from its price of NT$106 on 08 October 2020. The Taiwanese market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 5.0% over the same period.分析記事 • Dec 11Breakeven On The Horizon For Applied BioCode Corporation (TPE:6598)We feel now is a pretty good time to analyse Applied BioCode Corporation's ( TPE:6598 ) business as it appears the...Is New 90 Day High Low • Dec 02New 90-day low: NT$72.70The company is down 48% from its price of NT$139 on 03 September 2020. The Taiwanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 1.0% over the same period.Reported Earnings • Nov 14Third quarter 2020 earnings released: NT$0.28 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: NT$97.4m (up 191% from 3Q 2019). Net loss: NT$23.1m (loss narrowed 67% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 16% per year.Is New 90 Day High Low • Oct 28New 90-day low: NT$77.80The company is down 24% from its price of NT$102 on 30 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 8.0% over the same period.Is New 90 Day High Low • Oct 13New 90-day low: NT$92.50The company is down 19% from its price of NT$114 on 15 July 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 16% over the same period.お知らせ • Jul 22Applied BioCode Corporation To Be Deleted From Other OTCApplied BioCode Corporation Corp. Common Stock will be deleted from Other OTC effective July 13, 2020. The deletion was due to Inactive Security.株主還元6598TW Medical EquipmentTW 市場7D21.0%-4.4%-6.3%1Y35.9%-28.3%80.7%株主還元を見る業界別リターン: 6598過去 1 年間で-28.3 % の収益を上げたTW Medical Equipment業界を上回りました。リターン対市場: 6598は、過去 1 年間で80.7 % のリターンを上げたTW市場を下回りました。価格変動Is 6598's price volatile compared to industry and market?6598 volatility6598 Average Weekly Movement5.8%Medical Equipment Industry Average Movement4.7%Market Average Movement6.6%10% most volatile stocks in TW Market12.1%10% least volatile stocks in TW Market2.6%安定した株価: 6598 、 TW市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 6598の 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2016n/aWinston Z. Howww.apbiocode.comアプライド・バイオコード・コーポレーションは、カリフォルニア州でマルチプレックス診断検査製品の設計、開発、商品化を行っている。同社の製品には、分子検査のPCR増幅、ハイブリダイゼーション、検出ステップを自動化する自動分子診断システムBioCode MDx 3000システムや、バーコード付き磁気ビーズ（BMB）を読み取り、各BMBのバーコードと蛍光強度を表示するシステムBioCode 2500 analyzerなどがある。また、鼻咽頭ぬぐい液中のSARS-CoV-2核酸を検出する核酸アッセイBioCode SARS-CoV-2 Assay、RNAや各種インフルエンザを検出するCoV-2 Flu Assayなどのアッセイを開発し、消化器・呼吸器病原体パネル関連製品を提供している。加えて、同社は汎用試薬を提供し、28種類の真菌分析に特化した試薬を製造している。さらに、バーコード付きビーズ関連のアクセサリーも提供している。アプライド・バイオコード・コーポレーションはカリフォルニア州サンタフェスプリングスを拠点としている。もっと見るApplied BioCode Corporation 基礎のまとめApplied BioCode の収益と売上を時価総額と比較するとどうか。6598 基礎統計学時価総額NT$2.84b収益（TTM）-NT$144.49m売上高(TTM)NT$572.33m5.0xP/Sレシオ-19.7xPER（株価収益率6598 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計6598 損益計算書（TTM）収益NT$572.33m売上原価NT$251.97m売上総利益NT$320.36mその他の費用NT$464.85m収益-NT$144.49m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-1.41グロス・マージン55.97%純利益率-25.25%有利子負債／自己資本比率0%6598 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/18 22:24終値2026/07/17 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Applied BioCode Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Xiaowei HuangMasterlink Securities Investment Advisory
Reported Earnings • May 16First quarter 2026 earnings released: EPS: NT$0.20 (vs NT$0.35 loss in 1Q 2025)First quarter 2026 results: EPS: NT$0.20 (up from NT$0.35 loss in 1Q 2025). Revenue: NT$217.1m (up 81% from 1Q 2025). Net income: NT$21.0m (up NT$56.7m from 1Q 2025). Profit margin: 9.7% (up from net loss in 1Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
お知らせ • May 05Applied BioCode Announces FDA Clearance for KingFisher™ Nucleic Acid Extraction with BioCode® Respiratory Pathogen Panel for IVD UseApplied BioCode, a leader in multiplex molecular diagnostic solutions, announced a significant enhancement to its BioCode Respiratory Pathogen Panel (RPP) workflow with the addition of nucleic acid extraction claims for the widely used Thermo Fisher Scientific KingFisher Flex platform. This expansion provides clinical laboratories running BioCode RPP with greater workflow flexibility and optimized sample processing capabilities. This enhancement to the BioCode RPP enables seamless integration of the KingFisher Flex extraction platform and the BioCode MDx-3000 automated detection system, expanding the panel’s utility and increasing throughput for respiratory testing. Clinical laboratories using these extraction systems can now streamline their workflows by pairing them with the BioCode RPP, providing an affordable and comprehensive solution for detecting 17 prevalent respiratory pathogens. By improving workflow efficiency, this new claim is expected to enhance patient care by accelerating the delivery of accurate and timely diagnostic results. This submission builds on Applied BioCode’s previous FDA clearance of the BioCode Gastrointestinal Pathogen Panel (GPP) with the KingFisher Flex system, highlighting the company’s ongoing success in validating flexible, high-throughput extraction solutions across its multiplexed panel portfolio. Applied BioCode continues to advance molecular diagnostic solutions that meet the evolving needs of clinical laboratories, supporting patient care with accurate, reliable, and actionable results.
Reported Earnings • Mar 13Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: NT$1.96 loss per share (improved from NT$2.88 loss in FY 2024). Revenue: NT$475.2m (up 39% from FY 2024). Net loss: NT$201.2m (loss narrowed 23% from FY 2024). Revenue missed analyst estimates by 5.0%. Earnings per share (EPS) also missed analyst estimates by 17%. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has fallen by 4% per year.
お知らせ • Mar 12Applied BioCode Corporation, Annual General Meeting, Jun 11, 2026Applied BioCode Corporation, Annual General Meeting, Jun 11, 2026, at 10:00 Taipei Standard Time. Location: 7 floor no,185, hsin hu 1st rd., neihu district, taipei city Taiwan
Board Change • Dec 30Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Jim Wu was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 12Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2025 results: NT$0.33 loss per share (improved from NT$0.80 loss in 3Q 2024). Revenue: NT$122.8m (up 64% from 3Q 2024). Net loss: NT$33.7m (loss narrowed 56% from 3Q 2024). Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 23%. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 8% per year.
Reported Earnings • May 16First quarter 2026 earnings released: EPS: NT$0.20 (vs NT$0.35 loss in 1Q 2025)First quarter 2026 results: EPS: NT$0.20 (up from NT$0.35 loss in 1Q 2025). Revenue: NT$217.1m (up 81% from 1Q 2025). Net income: NT$21.0m (up NT$56.7m from 1Q 2025). Profit margin: 9.7% (up from net loss in 1Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
お知らせ • May 05Applied BioCode Announces FDA Clearance for KingFisher™ Nucleic Acid Extraction with BioCode® Respiratory Pathogen Panel for IVD UseApplied BioCode, a leader in multiplex molecular diagnostic solutions, announced a significant enhancement to its BioCode Respiratory Pathogen Panel (RPP) workflow with the addition of nucleic acid extraction claims for the widely used Thermo Fisher Scientific KingFisher Flex platform. This expansion provides clinical laboratories running BioCode RPP with greater workflow flexibility and optimized sample processing capabilities. This enhancement to the BioCode RPP enables seamless integration of the KingFisher Flex extraction platform and the BioCode MDx-3000 automated detection system, expanding the panel’s utility and increasing throughput for respiratory testing. Clinical laboratories using these extraction systems can now streamline their workflows by pairing them with the BioCode RPP, providing an affordable and comprehensive solution for detecting 17 prevalent respiratory pathogens. By improving workflow efficiency, this new claim is expected to enhance patient care by accelerating the delivery of accurate and timely diagnostic results. This submission builds on Applied BioCode’s previous FDA clearance of the BioCode Gastrointestinal Pathogen Panel (GPP) with the KingFisher Flex system, highlighting the company’s ongoing success in validating flexible, high-throughput extraction solutions across its multiplexed panel portfolio. Applied BioCode continues to advance molecular diagnostic solutions that meet the evolving needs of clinical laboratories, supporting patient care with accurate, reliable, and actionable results.
Reported Earnings • Mar 13Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: NT$1.96 loss per share (improved from NT$2.88 loss in FY 2024). Revenue: NT$475.2m (up 39% from FY 2024). Net loss: NT$201.2m (loss narrowed 23% from FY 2024). Revenue missed analyst estimates by 5.0%. Earnings per share (EPS) also missed analyst estimates by 17%. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has fallen by 4% per year.
お知らせ • Mar 12Applied BioCode Corporation, Annual General Meeting, Jun 11, 2026Applied BioCode Corporation, Annual General Meeting, Jun 11, 2026, at 10:00 Taipei Standard Time. Location: 7 floor no,185, hsin hu 1st rd., neihu district, taipei city Taiwan
Board Change • Dec 30Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Jim Wu was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 12Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2025 results: NT$0.33 loss per share (improved from NT$0.80 loss in 3Q 2024). Revenue: NT$122.8m (up 64% from 3Q 2024). Net loss: NT$33.7m (loss narrowed 56% from 3Q 2024). Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 23%. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 8% per year.
Reported Earnings • Aug 27Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: NT$0.66 loss per share (further deteriorated from NT$0.61 loss in 2Q 2024). Revenue: NT$115.9m (up 14% from 2Q 2024). Net loss: NT$67.5m (loss widened 35% from 2Q 2024). Revenue missed analyst estimates by 7.3%. Earnings per share (EPS) also missed analyst estimates by 53%. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.
お知らせ • Jun 07Applied BioCode Corporation Approves Board ElectionsApplied BioCode Corporation at its 2025 Shareholders' General Meeting held on June 6, 2025, approved the election of George J. Lee, Director, Foresee Pharmaceuticals Co. Ltd. and Benjamin Jen, Managing Partner, GRC SinoGreen Fund as Directors. Title and name of the previous position holder: Representative of institutional directors: Independent Director: Ben Liu, Lawyer, InfoShare Tech Law Office and Independent Director: Jack Hsiao, COO, Hsiao Chung-Cheng Healthcare group. Title and name of the new position holder: Representative of institutional directors: Independent Director: James Hsu, Director, TaChuan Investment Ltd. and Independent Director: Jim Wu, Director and Chief Corporate Affairs Officer, TNL Mediagene. Effective date of the new appointment is June 6, 2025.
Reported Earnings • May 15First quarter 2025 earnings released: NT$0.35 loss per share (vs NT$0.77 loss in 1Q 2024)First quarter 2025 results: NT$0.35 loss per share (improved from NT$0.77 loss in 1Q 2024). Revenue: NT$120.0m (up 47% from 1Q 2024). Net loss: NT$35.7m (loss narrowed 43% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.
お知らせ • May 01Applied BioCode Corporation to Report Q1, 2025 Results on May 08, 2025Applied BioCode Corporation announced that they will report Q1, 2025 results on May 08, 2025
Reported Earnings • Mar 20Full year 2024 earnings released: NT$2.88 loss per share (vs NT$2.01 loss in FY 2023)Full year 2024 results: NT$2.88 loss per share (further deteriorated from NT$2.01 loss in FY 2023). Revenue: NT$343.1m (down 13% from FY 2023). Net loss: NT$260.8m (loss widened 59% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings.
お知らせ • Mar 14Applied BioCode Corporation, Annual General Meeting, Jun 06, 2025Applied BioCode Corporation, Annual General Meeting, Jun 06, 2025.
お知らせ • Mar 06Applied BioCode Corporation to Report Q4, 2024 Results on Mar 13, 2025Applied BioCode Corporation announced that they will report Q4, 2024 results at 9:00 AM, Taipei Standard Time on Mar 13, 2025
お知らせ • Jan 14Applied Biocode Announces New Nucleic Acid Extraction Claim for Kingfisher Flex Nucleic Acid Purification System with Biocode Gastrointestinal Pathogen Panel (GPP)Applied BioCode announced a significant enhancement to its BioCode Gastrointestinal Pathogen Panel (GPP) with the addition of nucleic acid extraction claim for the widely adopted ThermoFisher Scientific KingFisher Flex platform. This expansion enables greater workflow flexibility and optimized sample processing capabilities for clinical laboratories running the BioCode GPP. This enhancement to the BioCode GPP allows for seamless integration with KingFisher Flex extraction platform, broadening the panel’s utility and increasing throughput for gastrointestinal testing. Clinical laboratories using these extraction systems can now streamline their operations by pairing them with the BioCode GPP, providing a comprehensive solution to detect 17 of the most prevalent gastrointestinal pathogens. By improving workflow efficiency, the new claim is expected to significantly impact patient care by accelerating the turnaround of accurate and timely diagnostic information. The BioCode GPP now supports multiple extraction platforms, making it one of the most versatile panels in its class for detecting gastrointestinal pathogens in stool samples. This addition aligns with Applied BioCode’s mission to innovate and adapt to the growing demands of healthcare providers, enabling laboratories to maximize the value of their existing instruments while advancing diagnostic capabilities. With its unique Barcoded Magnetic Bead (BMB) technology, the BioCode GPP simplifies and accelerates high-throughput molecular diagnostics, offering an economical, accurate, and comprehensive solution for clinical labs across the U.S. and beyond. This nucleic acid extraction expansion will help laboratories improve their workflows, increase operational flexibility, and expand their diagnostic capabilities.
New Risk • Nov 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (NT$2.29b market cap, or US$70.4m).
Reported Earnings • Nov 18Third quarter 2024 earnings: EPS and revenues miss analyst expectationsThird quarter 2024 results: NT$0.80 loss per share (further deteriorated from NT$0.54 loss in 3Q 2023). Revenue: NT$74.9m (down 29% from 3Q 2023). Net loss: NT$76.8m (loss widened 76% from 3Q 2023). Revenue missed analyst estimates by 33%. Earnings per share (EPS) also missed analyst estimates by 82%. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 10% per year.
お知らせ • Nov 02Applied BioCode Corporation to Report Q3, 2024 Results on Nov 11, 2024Applied BioCode Corporation announced that they will report Q3, 2024 results on Nov 11, 2024
Reported Earnings • Aug 29Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2024 results: NT$0.61 loss per share (improved from NT$0.75 loss in 2Q 2023). Revenue: NT$101.6m (up 30% from 2Q 2023). Net loss: NT$50.0m (loss narrowed 18% from 2Q 2023). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) missed analyst estimates by 11%. Over the last 3 years on average, earnings per share has fallen by 13% per year whereas the company’s share price has fallen by 14% per year.
お知らせ • Aug 15Applied BioCode Corporation to Report Q2, 2024 Results on Aug 22, 2024Applied BioCode Corporation announced that they will report Q2, 2024 results on Aug 22, 2024
お知らせ • Jul 20Applied BioCode Corporation announced that it has received fundingApplied BioCode Corporation announced a private placement to issue common shares on July 19, 2024. The transaction has been approved by shareholders of company.
New Risk • Jun 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (NT$2.75b market cap, or US$84.8m).
分析記事 • Jun 19Applied BioCode Corporation's (TWSE:6598) Shares Climb 33% But Its Business Is Yet to Catch UpThe Applied BioCode Corporation ( TWSE:6598 ) share price has done very well over the last month, posting an excellent...
Reported Earnings • May 19First quarter 2024 earnings: EPS and revenues miss analyst expectationsFirst quarter 2024 results: NT$0.77 loss per share (further deteriorated from NT$0.62 loss in 1Q 2023). Revenue: NT$81.5m (down 1.5% from 1Q 2023). Net loss: NT$63.1m (loss widened 24% from 1Q 2023). Revenue missed analyst estimates by 9.4%. Earnings per share (EPS) also missed analyst estimates by 71%. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings.
お知らせ • Apr 15Applied BioCode Announces the Launch of the STI + Resistance Panel Assay for Research Use OnlyApplied BioCode Inc. announced the launch of its latest innovation, the BioCode STI + Resistance Panel (RUO). This multiplex nucleic acid amplification test is meticulously crafted to qualitatively detect DNA from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), Mycoplasma genitalium (MG), as well as macrolide-resistant and fluoroquinolone-resistant single nucleotide polymorphism (SNP) mutations in a single reaction. The panel is exclusively intended for research purposes and is not intended for diagnostic procedures. Engineered with precision for seamless integration with the BioCode MDx-3000 automated system, it delivers timely test results approximately 4 hours post-DNA extraction. The system boasts an intuitive protocol and reporting software, meticulously tailored to enhance workflows in research clinical microbiology lab environments, accommodating up to 96 samples per test run.
お知らせ • Mar 22Applied BioCode Announces CEO ChangesApplied BioCode announced the retirement of Chris Bernard as Chief Executive Officer. Chris Bernard has served as CEO for the past two years and has been instrumental in guiding the company through a period of growth and innovation. During his tenure, Chris played a pivotal role in advancing Applied BioCode’s strategic initiatives and driving the company’s commitment to delivering cutting-edge solutions to the molecular diagnostics market. His leadership and dedication have been invaluable in positioning Applied BioCode as a leader in multiplex testing technologies. Following his retirement, Winston Ho, Ph.D., Founder and President, will step into the role of Chief Executive Officer until a new CEO is appointed.
Reported Earnings • Mar 17Full year 2023 earnings released: NT$2.01 loss per share (vs NT$2.26 loss in FY 2022)Full year 2023 results: NT$2.01 loss per share (improved from NT$2.26 loss in FY 2022). Revenue: NT$395.2m (up 1.2% from FY 2022). Net loss: NT$164.2m (loss narrowed 11% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 23% per year and the company’s share price has also fallen by 23% per year.
お知らせ • Mar 08Applied BioCode Corporation, Annual General Meeting, May 27, 2024Applied BioCode Corporation, Annual General Meeting, May 27, 2024. Location: Lily Conference, (2F, No. 327, Sec. 1, Tiding Blvd., Neihu Dist Taipei City Taiwan Agenda: To consider 2023 operation report; to consider audit committee review report on the 2023 financial statements; to consider amendment to the rules of procedures for the board of directors meeting; to consider 2023 business report and 2023 consolidated financial report; to consider 2023 deficit compensation; to consider adoption of the amended and restated memorandum and articles of association; to consider amendment to procedures for acquisition or disposal of assets; and to consider other issues.
New Risk • Dec 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.9% average weekly change). Market cap is less than US$100m (NT$2.13b market cap, or US$67.8m).
Reported Earnings • Nov 15Third quarter 2023 earnings released: NT$0.53 loss per share (vs NT$0.54 loss in 3Q 2022)Third quarter 2023 results: NT$0.53 loss per share (improved from NT$0.54 loss in 3Q 2022). Revenue: NT$105.8m (down 1.9% from 3Q 2022). Net loss: NT$43.7m (flat on 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.
お知らせ • Sep 29Applied BioCode Appoints Beth Laderman as Chief Scientific OfficerApplied BioCode announced that Beth Laderman has been appointed as their new Chief Scientific Officer signaling a significant step in the company’s expansion. With 25 years of experience in the medical diagnostic field, Dr. Laderman brings expertise from her previous roles at HYCOR Biomedical and Biomerica Inc. Her appointment is set to drive Applied BioCode’s focus on expanding its MDx-3000 platform and exploring new applications for its patented barcoded magnetic beads (BMBs). Dr. Laderman joins as Applied BioCode continues to expand its US commercial footprint and explores US & global expansion and new opportunities for their technology. With its current portfolio of PCR-based, multiplex molecular diagnostic assays in the respiratory and gastrointestinal markets, along with the new BioCode Fungal Panel RUO approval, the company remains steadfast in its mission in having R&D fully support the commercial enterprise by delivering transformative solutions for high-throughput diagnostics. Dr. Laderman’s appointment as CSO of Applied BioCode marks an exciting chapter in the company’s journey to revolutionize diagnostics and life sciences. Her deep knowledge, leadership skills, and dedication to innovation are expected to drive the company’s research and development initiatives to new heights.
お知らせ • Sep 25Applied BioCode Corporation Announces the Resignation of Michael Sean Aye as Research and Development OfficerApplied BioCode Corporation announced the resignation of Michael Sean Aye as research and development officer, effective September 23, 2023. Reason for the change: Personal career planning.
Reported Earnings • Aug 30Second quarter 2023 earnings released: NT$0.75 loss per share (vs NT$0.39 loss in 2Q 2022)Second quarter 2023 results: NT$0.75 loss per share (further deteriorated from NT$0.39 loss in 2Q 2022). Revenue: NT$78.5m (down 27% from 2Q 2022). Net loss: NT$61.2m (loss widened 94% from 2Q 2022). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings.
お知らせ • Jun 15Applied BioCode Corporation Announces the Change of Representative of Institutional DirectorApplied BioCode Corporation announced Name of the previous position holder:Wen-Chin Hung. Resume of the previous position holder:Wen-Chin Hung/Mingwei Corporation. 5.Name of the new position holder:Lizzie lee. Resume of the new position holder:Lizzie Lee/GRC SinoGreen Capital Co. Ltd. Risk Management Director. Reason for the change: Institutional director assigned a representative.
お知らせ • Jun 13Applied Biocode Corporation Announces the Launch of the Fungal Panel Assay for Research UseApplied BioCode Corporation announced that it now offers Fungal Panel on the BioCode® MDx-3000 system for research use only (RUO). The Fungal Panel Assay was developed to detect the most common agents of invasive fungal infections (IFIs) particularly in lower respiratory samples. This Panel detects fungal agents includingAspergillus species, Rhizopus, Mucor, Rhizomucor, Cunninghamella, Lomentospora, Fusarium, Cryptococcus, Pneumocystis jirovecii and dimorphic pathogens (Coccidioides immitis/posadasii, Histoplasma capsulatum and Blastomyces dermatiditis). The panel will provide 20 distinct results along with an internal control and will be primarily for use on the company's BioCode MDx-3000 instrument. Detection of IFI is difficult, and recovery by culture could take several days to weeks with poor sensitivity. Faster and more sensitive detection of IFI can be helpful in clinical management, especially for immunocompromised patients.
Reported Earnings • Mar 26Full year 2022 earnings: Revenues and EPS in line with analyst expectationsFull year 2022 results: NT$2.26 loss per share (further deteriorated from NT$2.02 loss in FY 2021). Revenue: NT$390.3m (up 22% from FY 2021). Net loss: NT$184.7m (loss widened 12% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
お知らせ • Jan 05Applied BioCode Corporation Announces Resignation of Craig Griz Adams as Sales DirectorApplied BioCode Corporation announced resignation of Craig Griz Adams as Sales Director due to personal career planning, effective January 4, 2023.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Director Benjamin Jen was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Director Benjamin Jen was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Oct 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Director Benjamin Jen was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 26+ 1 more updateApplied BioCode Corporation Announces the Change of Vice President of OperationApplied BioCode Corporation announced the Change of Vice President of Operation. Date of occurrence of the change is August 25, 2022. Name, title, and resume of the previous position holder: N/A. Name, title, and resume of the new position holder: Gerald Kowalski/The Company's Director of Product Development. Type of the change: position adjustment. Reason for the change: Gerald Kowalski was the Director of Product Development and then is promoted to VP of Operation due to the internal position adjustment. Effective date is August 25, 2022.
お知らせ • May 18Applied BioCode Corporation Announces Change of Sales DirectorApplied BioCode Corporation announced change of Sales Director. Name, title, and resume of the previous position holder: Michael Jason Scott/Sales Director. Type of the change: Resignation. Effective date is May 17, 2022.
Reported Earnings • May 14First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: NT$0.90 loss per share (down from NT$0.29 loss in 1Q 2021). Revenue: NT$54.1m (down 36% from 1Q 2021). Net loss: NT$73.8m (loss widened 209% from 1Q 2021). Revenue exceeded analyst estimates by 10.0%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Price Target Changed • Apr 27Price target decreased to NT$34.00Down from NT$102, the current price target is provided by 1 analyst. New target price is 27% below last closing price of NT$46.75. Stock is down 8.5% over the past year. The company is forecast to post a net loss per share of NT$2.24 next year compared to a net loss per share of NT$2.02 last year.
Reported Earnings • Mar 31Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: NT$2.02 loss per share (down from NT$1.33 loss in FY 2020). Revenue: NT$320.0m (up 7.0% from FY 2020). Net loss: NT$165.2m (loss widened 60% from FY 2020). Revenue exceeded analyst estimates by 10.0%. Earnings per share (EPS) missed analyst estimates by 15%. Over the next year, revenue is forecast to stay flat compared to a 31% growth forecast for the industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
お知らせ • Dec 17Applied BioCode Obtains Emergency Use Authorization for CoV-2 Flu Plus AssayApplied BioCode announced that it has received Emergency Use Authorization (EUA) from the US FDA for its BioCode® CoV-2 Flu Plus Assay. This PCR-based, multiplex molecular diagnostic assay can simultaneously detect and differentiate between SARS-CoV-2, Influenza A with subtypes (seasonal H1, 2009 H1N1, H3, Influenza B), and Respiratory Syncytial Virus (RSV) in nasopharyngeal swab specimens. The test is designed to assist physicians in evaluating patients with clinical signs and symptoms respiratory infection. The BioCode® CoV-2 Flu Plus Assay is Applied BioCode’s third EUA authorization from the US FDA for COVID-19 testing. Applied BioCode previously received FDA EUA authorization for the BioCode® SARS CoV-2 Assay and for pooling of up to 5 samples for that assay. The BioCode® CoV-2 Flu Plus Assay is run on the automated high-throughput BioCode® MDx-3000 Molecular System and provides scalable throughput, allowing clinical labs to run up to 564 sample results per day. BioCode® CoV-2 Flu Plus Assay builds on the existing portfolio of high-throughput syndromic assays from Applied BioCode including the FDA 510(k) cleared BioCode Respiratory Pathogen Panel (17 targets), FDA 510(k) cleared BioCode® Gastrointestinal Pathogen Panel (17 targets), and its stand-alone EUA authorized BioCode® SARS-CoV-2 Assay.
お知らせ • Nov 24Applied BioCode Launches 28 New Fungal Analyte Specific Reagents in the USApplied BioCode announced that it has released28 Fungal Analyte Specific Reagents (ASRs) for use in molecular tests. (15 ASRs for mold pathogens, 10 ASRs for yeast pathogens, and 3 ASRs to detect dimorphic fungi). These ASR products utilize the company’s proprietary Barcoded Magnetic Bead (BMB) technology for specific detection of targeted organisms. For use as building blocks to develop and validate tests for the diagnosis of infectious diseases, ASRs may be sold to in vitro diagnostic manufacturers, and clinical laboratories regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), as qualified to perform high complexity testing. ASRs may also be sold to organizations that use the reagents to make tests for purposes other than providing diagnostic information to patients and practitioners, e.g., forensic, academic, research, and other nonclinical laboratories. The primer pairs or probes coupled to BMBs are classified as ASRs, which can be used by high-complexity laboratories to develop their own laboratory developed tests (LDTs).
Reported Earnings • Nov 12Third quarter 2021 earnings released: NT$0.75 loss per share (vs NT$0.28 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: NT$58.8m (down 40% from 3Q 2020). Net loss: NT$61.1m (loss widened 165% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
分析記事 • Mar 31We're Interested To See How Applied BioCode (TPE:6598) Uses Its Cash Hoard To GrowThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Reported Earnings • Mar 30Full year 2020 earnings released: NT$1.33 loss per share (vs NT$4.36 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: NT$299.0m (up 186% from FY 2019). Net loss: NT$103.5m (loss narrowed 63% from FY 2019). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
お知らせ • Mar 18Applied BioCode Corporation, Annual General Meeting, Jun 07, 2021Applied BioCode Corporation, Annual General Meeting, Jun 07, 2021.
分析記事 • Feb 03Introducing Applied BioCode (TPE:6598), A Stock That Climbed 11% In The Last Three YearsThe last three months have been tough on Applied BioCode Corporation ( TPE:6598 ) shareholders, who have seen the share...
Is New 90 Day High Low • Feb 02New 90-day low: NT$49.05The company is down 38% from its price of NT$79.60 on 04 November 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 10.0% over the same period.
Is New 90 Day High Low • Jan 07New 90-day low: NT$55.00The company is down 48% from its price of NT$106 on 08 October 2020. The Taiwanese market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 5.0% over the same period.
分析記事 • Dec 11Breakeven On The Horizon For Applied BioCode Corporation (TPE:6598)We feel now is a pretty good time to analyse Applied BioCode Corporation's ( TPE:6598 ) business as it appears the...
Is New 90 Day High Low • Dec 02New 90-day low: NT$72.70The company is down 48% from its price of NT$139 on 03 September 2020. The Taiwanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 1.0% over the same period.
Reported Earnings • Nov 14Third quarter 2020 earnings released: NT$0.28 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: NT$97.4m (up 191% from 3Q 2019). Net loss: NT$23.1m (loss narrowed 67% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 16% per year.
Is New 90 Day High Low • Oct 28New 90-day low: NT$77.80The company is down 24% from its price of NT$102 on 30 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 8.0% over the same period.
Is New 90 Day High Low • Oct 13New 90-day low: NT$92.50The company is down 19% from its price of NT$114 on 15 July 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 16% over the same period.
お知らせ • Jul 22Applied BioCode Corporation To Be Deleted From Other OTCApplied BioCode Corporation Corp. Common Stock will be deleted from Other OTC effective July 13, 2020. The deletion was due to Inactive Security.
